The primary objective of the “Patient Reported Outcomes in high risk and advanced MELanoma patients” (PRO-MEL) study is to assess HRQoL in high risk and advanced melanoma patients treated with immune checkpoint-inhibitors. Secondary outcomes are anxiety and depression; fear of cancer recurrence; melanoma-specific HRQoL; treatment-related symptoms; work ability; and information needs in high risk and advanced melanoma patients treated with immune checkpoint-inhibitors.